In 2024, the trade exchange (includes international purchases and sales) of Heterocyclic Compounds Containing in the Structure Benzothiazole, Incl. Hydrogenated, not further Fused was US$27.9M.
In 2024, the states with the most international sales in Heterocyclic Compounds Containing in the Structure Benzothiazole, Incl. Hydrogenated, not further Fused were Baja California (US$148k), Estado de México (US$97k), Ciudad de México (US$30.1k), and Guanajuato (US$8.28k).
The states with the most international purchases in 2024 were Querétaro (US$10.9M), Ciudad de México (US$5.67M), San Luis Potosí (US$3.81M), Guanajuato (US$3.78M), and Estado de México (US$2.06M).
In 2024, the main commercial destinations of Heterocyclic Compounds Containing in the Structure Benzothiazole, Incl. Hydrogenated, not further Fused were United States (US$149k), Cuba (US$39.9k), El Salvador (US$29k), China (US$24.9k), and Guatemala (US$14.1k).
The main commercial origins of Heterocyclic Compounds Containing in the Structure Benzothiazole, Incl. Hydrogenated, not further Fused in 2024 were China (US$22.6M), Belgium (US$2.78M), United States (US$1.05M), India (US$1.03M), and Japan (US$74.4k).
In the global context, the main exporting countries of Heterocyclic Compounds Containing in the Structure Benzothiazole, Incl. Hydrogenated, not further Fused in 2022 were China (US$496M), Belgium (US$105M), and Spain (US$52.5M). In the same year, the main importing countries of Heterocyclic Compounds Containing in the Structure Benzothiazole, Incl. Hydrogenated, not further Fused were United States (US$143M), Germany (US$79.2M), and Japan (US$68.3M).